KMPHARMACEUTICAL Co.,Ltd. (KOSDAQ:225430)
South Korea · Delayed Price · Currency is KRW 516.00
+24.00 (4.88%)
At close: Feb 26, 2026
KMPHARMACEUTICAL Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 15,093 | 14,475 | 17,770 | 15,631 | 22,705 | 22,928 |
Other Revenue | 0 | - | - | -0 | -0 | - |
| 15,093 | 14,475 | 17,770 | 15,631 | 22,705 | 22,928 | |
Revenue Growth (YoY) | 3.76% | -18.54% | 13.68% | -31.16% | -0.97% | 12.73% |
Cost of Revenue | 11,232 | 10,869 | 12,859 | 12,407 | 17,042 | 16,988 |
Gross Profit | 3,861 | 3,606 | 4,910 | 3,225 | 5,663 | 5,941 |
Selling, General & Admin | 4,960 | 4,865 | 4,976 | 3,219 | 3,948 | 4,537 |
Research & Development | 837.16 | 559.98 | 298.31 | 450.38 | 404.56 | 306.7 |
Amortization of Goodwill & Intangibles | 6.74 | 28.2 | 39.18 | 39.44 | 39.29 | 38.97 |
Other Operating Expenses | 83.72 | 76.4 | 59.75 | 59.04 | 59.54 | 138.13 |
Operating Expenses | 7,630 | 7,453 | 6,024 | 6,946 | 4,797 | 5,228 |
Operating Income | -3,768 | -3,848 | -1,113 | -3,722 | 866.14 | 712.32 |
Interest Expense | -593.46 | -582.34 | -613.68 | -384.49 | -173.49 | -495.16 |
Interest & Investment Income | 657.44 | 672.3 | 675.68 | 431.1 | 52.57 | 51.15 |
Currency Exchange Gain (Loss) | -10 | -1.59 | -6.09 | -12.15 | -15.66 | -15.23 |
Other Non Operating Income (Expenses) | -49.93 | -100.64 | 17.67 | -16.74 | -74.01 | 57.99 |
EBT Excluding Unusual Items | -3,764 | -3,860 | -1,040 | -3,704 | 655.55 | 311.07 |
Gain (Loss) on Sale of Investments | -446.69 | -389.25 | 74.79 | -61.63 | -674.13 | 15.99 |
Gain (Loss) on Sale of Assets | - | -0.21 | 10.42 | - | 6.56 | -4.66 |
Asset Writedown | - | - | -9.19 | -808.27 | -501.8 | - |
Pretax Income | -4,211 | -4,249 | -963.76 | -4,574 | -513.83 | 322.4 |
Income Tax Expense | 466.64 | 323.93 | 356.29 | -649.05 | 97.36 | -148.48 |
Net Income | -4,678 | -4,573 | -1,320 | -3,925 | -611.19 | 470.88 |
Net Income to Common | -4,678 | -4,573 | -1,320 | -3,925 | -611.19 | 470.88 |
Shares Outstanding (Basic) | 28 | 28 | 28 | 28 | 28 | 21 |
Shares Outstanding (Diluted) | 28 | 28 | 28 | 28 | 28 | 21 |
Shares Change (YoY) | 1.47% | -0.71% | 0.90% | 0.20% | 29.80% | 2.06% |
EPS (Basic) | -167.45 | -163.99 | -47.00 | -141.00 | -22.00 | 22.00 |
EPS (Diluted) | -167.45 | -163.99 | -47.00 | -141.00 | -22.00 | 22.00 |
Free Cash Flow | -2,054 | -2,401 | 1,333 | -151.02 | -97.92 | -2,828 |
Free Cash Flow Per Share | -73.52 | -86.09 | 47.48 | -5.42 | -3.52 | -132.12 |
Gross Margin | 25.58% | 24.91% | 27.63% | 20.63% | 24.94% | 25.91% |
Operating Margin | -24.97% | -26.58% | -6.26% | -23.81% | 3.82% | 3.11% |
Profit Margin | -30.99% | -31.60% | -7.43% | -25.11% | -2.69% | 2.05% |
Free Cash Flow Margin | -13.61% | -16.59% | 7.50% | -0.97% | -0.43% | -12.33% |
EBITDA | -2,671 | -2,513 | 255.73 | -2,263 | 2,308 | 1,854 |
EBITDA Margin | -17.70% | -17.36% | 1.44% | -14.47% | 10.17% | 8.09% |
D&A For EBITDA | 1,097 | 1,335 | 1,369 | 1,459 | 1,442 | 1,142 |
EBIT | -3,768 | -3,848 | -1,113 | -3,722 | 866.14 | 712.32 |
EBIT Margin | -24.97% | -26.58% | -6.26% | -23.81% | 3.82% | 3.11% |
Advertising Expenses | - | 990.45 | 470.11 | 577.67 | 700.87 | 640.13 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.